Virus therapy takes on childhood brain cancer in early trial

NCT ID NCT03911388

First seen Feb 18, 2026 · Last updated Jun 11, 2026 · Updated 20 times

Summary

This early-phase study tests whether a specially engineered virus called G207 is safe for children whose cerebellar brain tumors have come back or not responded to standard treatments. Up to 24 children aged 3 to 21 will receive the virus directly into the tumor, along with a low dose of radiation to help the virus work better. The goal is to see if this approach can shrink tumors or boost the immune system against the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's of Alabama

    ACTIVE_NOT_RECRUITING

    Birmingham, Alabama, 35233, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St. Louis Children's Hospital

    ACTIVE_NOT_RECRUITING

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.